SCHEMBL1848031

SCHEMBL1848031

CC(C)(C)OC(=O)Nc1ccc(Cl)c(C(=O)Nc2c(C(N)=O)oc3ccc(Br)cc23)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.46
MAPT P10636 5/20 0.45
KMT2A Q03164 3/20 0.45
ALDH1A1 P00352 2/20 0.44
HPGD P15428 2/20 0.44
MEN1 O00255 2/20 0.44
TSHR P16473 1/20 0.44
HSD17B10 Q99714 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA9 Q16790 1/20 0.40
TP53 P04637 3/20 0.39
RORC P51449 1/20 0.39
RAB9A P51151 1/20 0.38
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
RECQL P46063 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1852128 0.86 HPGD (0.55) KDM4EMAPTKMT2AALDH1A1HPGD
SCHEMBL1850316 0.86 ALDH1A1 (0.50) KDM4EMAPTKMT2AALDH1A1HPGD
SCHEMBL4125534 0.84 HPGD (0.55) KDM4EMAPTKMT2AALDH1A1HPGD
SCHEMBL1851896 0.76 KMT2A (0.52) KDM4EMAPTKMT2AALDH1A1HPGD
SCHEMBL1853596 0.74 HPGD (0.52) KDM4EMAPTKMT2AALDH1A1HPGD
SCHEMBL1853653 0.73 ALDH1A1 (0.48) KDM4EMAPTKMT2AALDH1A1HPGD
SCHEMBL1849605 0.72 ALDH1A1 (0.47) KDM4EMAPTKMT2AALDH1A1HPGD
SCHEMBL1851522 0.71 MAPT (0.57) KDM4EMAPTKMT2AALDH1A1HPGD
SCHEMBL4273456 0.71 HPGD (0.52) KDM4EMAPTKMT2AALDH1A1HPGD
SCHEMBL1855922 0.70 RAB9A (0.43) KDM4EMAPTKMT2AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097419-B1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS INC (US) 2011-05-25 EP disclosed
EP-2097419-B1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS INC (US) 2011-05-25 EP disclosed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 US disclosed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 US disclosed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 US disclosed
WO-2009086264-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS, INC. (US) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247559-A1 Benzofuropyrimidinones F12, BRI3BP, BRD1 KDM4E 1855/4885MAPT 1941/4885KMT2A 2152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.